Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 19/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696966 | 0.83 | ALOX5 (0.61) | ALOX5 | |
| SCHEMBL9045890 | 0.82 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9025062 | 0.80 | ALOX5 (0.56) | ALOX5 | |
| SCHEMBL9078235 | 0.77 | ALOX5 (0.55) | ALOX5 | |
| SCHEMBL4540626 | 0.75 | ALOX5 (0.42) | ALOX5 | |
| SCHEMBL9024981 | 0.72 | ALOX5 (0.50) | ALOX5 | |
| SCHEMBL1680555 | 0.69 | ALOX5 (0.43) | ALOX5 | |
| SCHEMBL1733257 | 0.69 | ALOX5 (0.43) | ALOX5 | |
| SCHEMBL8783508 | 0.69 | ALOX5 (0.54) | ALOX5 | |
| SCHEMBL9045831 | 0.68 | ALOX5 (0.82) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| WO-1998058644-A1 | (S)-(-)-N-[3- [5-(4-FLUOROPHENOXY) -2-FURANYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| WO-1998058645-A1 | (S)-(-)-N-[3- [5-[(4-FLUOROPHENYL)METHYL] -2-THIENYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0731688-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | Abbott Laboratories (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015151-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LABORATORIES (US) | 1995-06-08 | — | — | WO | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | disclosed |
| WO-1998058644-A1 | (S)-(-)-N-[3- [5-(4-FLUOROPHENOXY) -2-FURANYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0731688-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | Abbott Laboratories (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015151-A1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LABORATORIES (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995005808-A1 | OIL-BASED TABLETING METHOD | ABBOTT LABORATORIES (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.